A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING ABT-494 TO PLACEBO AND TO ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE A HISTORY OF INADEQUATE RESPONSE TO AT LEAST ONE NON-BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUG (DMARD) ¿ SELECT ¿ PSA 1

Intervention/treatment:
UPADACITINIB (ABT-494)
Medical condition:
PSORIATIC ARTHRITIS
Protocol code:
M15-572
Control number:
204728
Status:
Closed
Approved:
May 24, 2017
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03104400
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Medical Services
Organization
AbbVie
Phone:
800-633-9110
Sponsor
ABBVIE CORPORATION

Locations

British Columbia

Percuro Clinical Research, Ltd /ID# 157823
Victoria, British Columbia, V8V 3M9

Manitoba

Ciads /Id# 157831
Winnipeg, Manitoba, R3N 0K6
Manitoba Clinic /ID# 157829
Winnipeg, Manitoba, R3A 1M3

Ontario

The Waterside Clinic /ID# 157826
Barrie, Ontario, L4M 6L2

Quebec

Ctr. de Recherche Musculo-Sque /ID# 207069
Trois-Rivières, Quebec, G8Z 1Y2
Groupe de Recherche en Maladies Osseuses Inc /ID# 157824
Sainte-Foy, Quebec, G1V 3M7

Results

See the results from the trial NCT03104400. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?